Emerging insight in genetics and therapies in young-onset Parkinson’s disease (YOPD): a comprehensive review
- 5 June 2026
- journal article
- review article
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 370
Abstract
Young-onset Parkinson’s disease (YOPD), defined as Parkinson's disease (PD) with onset between 21 and 50 years of age, represents 3–7% of all PD cases. YOPD is characterized by distinct genetic profiles, unique clinical manifestations, psychosocial challenges, and treatment responses compared to late-onset PD. Genetic mutations in PARK2, PINK1, DJ-1, SNCA, LRRK2, and GBA significantly contribute to the disease pathogenesis, influencing clinical outcomes and disease progression. Clinically, YOPD patients often present with rigidity, dystonia, and early motor fluctuations, alongside heightened psychiatric manifestations, significantly impacting quality of life. Advanced therapies, such as deep brain stimulation (DBS) and continuous subcutaneous apomorphine infusion (CSAI), offer substantial clinical benefit, although data specific to YOPD remain limited. Neuroimaging advancements provide insight into structural and functional brain alterations distinct to YOPD, facilitating earlier and more accurate diagnosis. This review synthesizes current knowledge on genetics, clinical features, psychosocial impacts, neuroimaging, and therapeutic approaches, underscoring the necessity for personalized multidisciplinary management strategies for YOPD.Keywords
This publication has 198 references indexed in Scilit:
- Characterization of Recessive Parkinson Disease in a Large Multicenter StudyAnnals of Neurology, 2020
- A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound TechnologyJAMA Neurology, 2018
- DNAJC6Mutations Associated With Early‐Onset Parkinson's DiseaseAnnals of Neurology, 2015
- New Clinical Subtypes of Parkinson Disease and Their Longitudinal ProgressionJAMA Neurology, 2015
- Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2010
- Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson DiseaseArchives of Neurology, 2009
- Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson DiseaseArchives of Neurology, 2009
- Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson DiseaseA Randomized Controlled TrialJAMA, 2009
- Drug selection and timing of initiation of treatment in early Parkinson's diseaseAnnals of Neurology, 2009
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000